Table 3.
Uni- and multivariate analyses of biochemical relapse-free rate.
| Risk factor | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Age | 0.96 | (0.88–1.05) | 0.78 | – | ||
| iPSA | ||||||
| < 10 | Ref | 0.00 | Ref | 0.00 | ||
| ≧10 | 10.1 | (2.30–44.40) | 10.70 | (2.69–42.89) | ||
| GS | 1.45 | (0.75–2.81) | 0.51 | – | ||
| T stage | ||||||
| < 3a | Ref | 0.72 | – | |||
| ≧3a | 1.45 | (0.18–11.70) | ||||
| Neoadjuvant ADT | ||||||
| No | Ref | 0.14 | Ref | 0.03 | ||
| Yes | 0.37 | (0.01–1.43) | 0.21 | (0.05–0.85) | ||
| Adjuvant ADT | ||||||
| No | Ref | 0.57 | – | |||
| Yes | 0.63 | (0.13–3.04) | ||||
| BED | 1.02 | (1.00–1.05) | 0.10 | 1.02 | (1.00–1.05) | 0.15 |
iPSA initial prostate cancer-specific antigen, GS Gleason score; BED biologically effective dose; ADT androgen deprivation therapy.